Guidant’s yang
This article was originally published in The Gray Sheet
Executive Summary
U.S. bare-metal stent sales decline 33% from Q3 2002 to $104 mil. Overall stent revenue fell 14%, to $200 mil., with the products to account for less than 10% of total revenue. Guidant spent about 15% of 2003 sales on R&D, deemed by CEO Ron Dollens a "year of investment, with returns in 2004 and 2005." Guidant projects 2003 sales of $3.65-$3.8 bil...